Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 6, 2013, Pages 1541-1550

  Zhao, Cuirong ^a   Li, Yuanyuan ^a   Qin, Yizhuo ^a   Wang, Ruiqi ^a   Li, Gang ^b   Sun, Changjun ^b   Qu, Xianjun ^a   Li, Wenbao ^b  

^a SHANDONG UNIVERSITY   (China)

^b Sanlugen PharmaTech Ltd   (China)

Author keywords

Gemcitabine; Metabolism; Pharmacokinetics; Prodrug; SL 01

Indexed keywords

AMINE; DODECY 3 [[1 [3,3DIFLUORO4 HYDROXY 5 (HYDROXYMETHYL) TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIMIDIN 4 YL] CARBAMOYL] PYRAZINE 2 CARBOXYLATE; GEMCITABINE; PRODRUG; SL 01; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHEMICAL BOND; DEALKYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; HYDROLYSIS; MALE; METABOLITE; METHYLATION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; INJECTIONS, INTRAVENOUS; MALE; MOLECULAR STRUCTURE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

EID: 84878658643     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2153-6     Document Type: Article

References (18)

1. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′- difluoro-2′-deoxycytidine). Cancer Res 50:4417-4422
2. Guchelaar HJ, Richel DJ, van Knapen A (1996) Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 22:15-31
3. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F (2005) Role of gemcitabine in cancer therapy. Future Oncol 1:7-17
4. Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, Slapak CA, Schellens JH (2008) Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 14:3477-3486
5. Kroep J, van Moorsel C, Veerman G, Voorn D, Schultz R, Worzalla J, Tanzer L, Merriman R, Pinedo H, Peters G (1998) Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC). Adv Exp Med Biol 431:657-660
6. Shipley L, Brown T, Cornpropst J, Hamilton M, Daniels W, Culp H (1992) Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20:849-855
7. Iwata K, Aizawa K, Sakai S, Jingami S, Fukunaga E, Yoshida M, Hamada A, Saito H (2011) The relationship between treatment time of gemcitabine and development of hematologic toxicity in cancer patients. Biol Pharm Bull 34:1765-1768
8. Huang J, Robertson JM, Ye H, Margolis J, Nadeau L, Yan D (2012) Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 83:1120-1125
9. Han HK, Amidon GL (2000) Targeted prodrug design to optimize drug delivery. AAPS Pharm Sci 2:48-58
10. Stella VJ (2010) Prodrugs: some thoughts and current issues. J Pharm Sci 99:4755-4765
11. Zhao CR, Xue XX, Li G, Sun CJ, Sun CC, Qu XJ, Li WB (2012) Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine. Chem Biol Drug Des 80:479-488
12. Xue XX, Li G, Sun CJ, Li WB (2009) Prodrugs based on gemcitabine structure as well as synthetic methods and the applications thereof. China Patent CN101525361A
13. Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA, Peterson JA, Perkins EJ, Pu YJ, Reutzel-Edens SM, Remick DM, Starling JJ, Stephenson GA, Vaid RK, Zhang D, McCarthy JR (2009) Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem 52:6958-6961
14. Zhao CR, Yue B, Liu HP, Sun CC, Li WB, Qu XJ (2012) SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine. Toxicol Appl Pharmacol 262:293-300
15. Wang H, Zhu QW, Ye P, Li ZB, Li Y, Cao ZL, Shen L (2012) Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2. Biosci Trends 6:325-332
16. Zhao T, Yang Y, Zong A, Tan H, Song X, Meng S, Song C, Pang G, Wang F (2012) N-terminal PEGylation of human serum albumin and investigation of its pharmacokinetics and pulmonary microvascular retention. Biosci Trends 6:81-88
17. Kaushal G, Shao J (2009) Vaginal delivery of protein drugs in rats by gene-transformed Lactococcus lactis. Drug Discov Ther 3:228-233
18. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095